Challenges of Investigator-initiated Clinical Trials to Support
the New Drug Development.
10.3779/j.issn.1009-3419.2022.102.31
- Author:
Hua BAI
1
;
Shuyang ZHANG
2
Author Information
1. Department of Scientific Research, Peking Union Medical College Hospital,
Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China.
2. Department of Cardiology, Peking Union Medical College Hospital,
Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China.
- Publication Type:Journal Article
- Keywords:
Ethical review;
Investigator-initiated clinical trials;
New drug development;
Quality management
- MeSH:
China;
Drug Development;
Humans;
Lung Neoplasms;
Research Personnel
- From:
Chinese Journal of Lung Cancer
2022;25(7):511-516
- CountryChina
- Language:Chinese
-
Abstract:
A large number of investigator-initiated clinical trials (IIT) were conducted in China, some of them should play an important supporting role in new drug development. Due to the large number, small scale and uneven quality of IIT in China, especially a big gap between the IIT and industry-sponsored trials in terms of protocol design, quality management and ethical review, many IIT can't be used to support the new drug development. Therefore, it is necessary for regulatory authorities, sponsors, research institutions, ethics committees and researchers to improve their understanding of the role of IIT. In order to support the new drug development with high-quality IIT, formulating supervising system, establishing an effective quality management system, enhancing the training of researchers and improving the ability of ethical review should be implemented effectively.
.
